Eli Lilly's stock price surged following impressive late-stage trial results for its next-generation weight-loss drug. The company also reported that its drug Jaypirca significantly reduced the risk of disease progression in CLL/SLL patients. Furthermore, Eli Lilly expanded its portfolio by acquiring 4E Therapeutics, a developer of non-addictive painkillers.
Eli Lilly has entered a strategic R&D collaboration and licensing agreement with Abbisko Therapeutics valued at up to $1.9 billion.
Read the full storyBioArctic will receive a $30 million upfront payment to leverage its technology in enhancing the delivery of Eli Lilly's drug candidates.
Eli Lilly acquires biotech firm 4E Therapeutics to develop safe alternatives to opioids, targeting a high-demand market for non-addictive pain management.
Phase 3 trials of Jaypirca demonstrated a 45% reduction in disease progression or death risk for CLL/SLL patients.
Shares of the pharmaceutical giant climbed in premarket trading after late-stage clinical trial data demonstrated high efficacy for its new obesity treatment.